For Immediate Release
Chicago, IL – April 5, 2013 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Priceline.com (PCLN), Equinix Inc. (EQIX), Pfizer Inc. (PFE), Novartis (NVS) and Bristol-Myers Squibb’s (BMY).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Thursday’s Analyst Blog:
Equinix Solution Helps Priceline
Like several other companies, Priceline.com (PCLN) is also taking support from Equinix Inc. (EQIX), which is using the Equinix Platform to improve the efficiency of its operation and meet the growing demands of the online travel industry.
Priceline has started using Equinix’s DC6 International Business Exchange data center, which is located in Ashburn, Virginia. This has been beneficial to Priceline, as it has reduced its server count by 40.0%, thereby reducing power consumption by 50%. Equinix’s solution is aiding Priceline to improve response time.
According to a joint study by Gartner and Frost & Sullivan, the Asia-Pacific will see maximum growth in the data center business. Gartner also expects China to become the second largest global data center market by 2015.
Through constant deal wins, the company has been able to add to its critical mass of customers and has expanded its network within IBX centers. Direct interconnection with its aggregation of networks, which serves more than 90% of the world’s Internet routes, enables customers to increase the efficiency of their IT infrastructure, remove complexities of administering and managing their infrastructure, while significantly reducing costs.
Although geographical expansion and deal wins are helping Equinix expand its business, its longer sales cycle means that revenues are not recognized immediately, so there may not be any rapid improvement in its results.
The current macroeconomic condition is further extending the sales cycle, as customers are unable to accurately forecast their future business plans and are therefore delaying their purchase decisions.
Conditional EU Approval for Pfizer’s Bosulif
Pfizer Inc. (PFE) recently announced it has gained conditional marketing authorization from the European Commission (EC) for its oncology product, Bosulif (bosutinib). Bosulif gained conditional EU approval for the treatment of adults suffering from chronic, accelerated, and blast phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) that has been previously treated with one or more tyrosine kinase inhibitors (TKIs) and for whom treatments like Novartis’ (NVS) Gleevec (imatinib) and Tasigna (nilotinib) and Bristol-Myers Squibb’s (BMY) Sprycel (dasatinib) are not considered suitable.
The conditional approval was expected as, earlier this year, the European Medicines Agency’s (:EMA) Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion regarding the conditional approval of Bosulif.
Conditional approval means that Pfizer will have to provide the EMA with additional efficacy and safety data on Bosulif. The approval is renewable on a yearly basis and could be converted into full marketing approval depending on the review of the additional data by the CHMP.
We note that Bosulif is already approved in the US. Pfizer gained US Food and Drug Administration (:FDA) approval in Sep 2012 for Bosulif for the treatment of chronic, accelerated, or blast phase Ph+ CML in adult patients who are resistant or intolerant to prior therapy. Bosulif enjoys orphan drug status in the US.
Pfizer currently carries a Zacks Rank #3 (Hold). While near-term earnings will be driven by cost cutting efforts and share repurchases, longer-term growth will depend on the success of drug development. Pfizer’s pipeline needs to deliver given the Lipitor loss of exclusivity and the upcoming loss of exclusivity on additional products in the next few years.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: https://twitter.com/zacksresearch
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
More From Zacks.com